寡合性氨酸减轻了喘严重程度和呼吸道重塑,通过调节上皮质-平滑肌肉细胞相互作用来减轻呼吸道重塑
Shengwei Gu1, Yihang Gu2, Hao Gu3
1Department of Pulmonary & Critical Care Medicine, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu 210029, PR China.
概括
在患者和小鼠中,Oligomeric proanthocyanidin (OPC) 补充剂改善了喘控制,并减少了呼吸道炎症和重塑. OPC通过减少氧化应激和细胞因子释放来减轻气道结构性细胞通信.
科学领域:
- 呼吸系统医学 呼吸系统医学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 呼吸道上皮细胞释放细胞因子,驱动喘病原和呼吸道重塑.
- 目前的喘管理策略的有效性有限.
- 葡萄种子中一种抗氧化剂的寡合蛋白氨酸 (OPC) 显示出喘的潜力,但其机制尚不清楚.
研究的目的:
- 为了研究OPC对喘的影响.
- 阐明OPC在喘中的作用的潜在机制.
主要方法:
- 临床试验涉及34名喘患者,随机分配给与OPC或没有OPC的布塞尼德/佛莫特罗尔.
- 用OPC治疗的OVA敏感小鼠中的喘模型.
- 使用人类支气管上皮细胞 (BE) 和呼吸道光滑肌肉 (ASM) 细胞进行体外研究,以研究OPC的细胞机制.
主要成果:
- 在患者中,OPC补充改善了喘控制,肺功能,并降低了乙氨基.
- 在小鼠中,OPC治疗减少了气道过敏反应,炎症,重塑和氧化应激.
- 通过减少细胞内ROS和通过p38通路抑制ASM细胞增殖,OPC降低了表皮衍生的细胞因子分泌 (eotaxin-1,TGF-β1).
结论:
- 在临床喘管理中,OPC显示出有前途的治疗潜力.
- OPC调节了气道结构细胞之间的通信,减轻了气道重塑.
- 这项研究强调OPC是减少喘呼吸道改造的有效选择.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
161
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
161
Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
Antiasthma Drugs: Leukotriene Modifiers
151
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
151
Asthma: Pathogenesis and Management
234
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
234
Antiasthma Drugs: Muscarinic Receptor Antagonists
137
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
137
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K


